Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Abnormalities, Drug-Induced | 24 | 2024 | 336 | 7.480 |
Why?
|
Pregnancy Complications | 41 | 2024 | 2970 | 5.300 |
Why?
|
Antipsychotic Agents | 24 | 2023 | 3075 | 3.510 |
Why?
|
Analgesics, Opioid | 31 | 2024 | 3834 | 2.640 |
Why?
|
Pregnancy | 126 | 2024 | 30230 | 2.600 |
Why?
|
Antiemetics | 6 | 2023 | 186 | 2.600 |
Why?
|
Pregnancy Trimester, First | 23 | 2024 | 917 | 2.550 |
Why?
|
Medicaid | 38 | 2024 | 2833 | 2.500 |
Why?
|
Antidepressive Agents | 17 | 2024 | 2901 | 2.250 |
Why?
|
Ondansetron | 5 | 2023 | 95 | 2.120 |
Why?
|
Prenatal Exposure Delayed Effects | 12 | 2024 | 2538 | 2.090 |
Why?
|
Neonatal Abstinence Syndrome | 6 | 2024 | 109 | 1.840 |
Why?
|
Sinusitis | 4 | 2024 | 995 | 1.800 |
Why?
|
Opioid-Related Disorders | 16 | 2024 | 2177 | 1.770 |
Why?
|
Amoxicillin-Potassium Clavulanate Combination | 2 | 2024 | 32 | 1.760 |
Why?
|
Drug Prescriptions | 17 | 2021 | 1662 | 1.640 |
Why?
|
Antithrombins | 4 | 2020 | 295 | 1.620 |
Why?
|
Methylphenidate | 4 | 2024 | 480 | 1.620 |
Why?
|
Amoxicillin | 2 | 2024 | 179 | 1.620 |
Why?
|
Propensity Score | 26 | 2021 | 1971 | 1.610 |
Why?
|
Valproic Acid | 3 | 2024 | 444 | 1.530 |
Why?
|
Cohort Studies | 83 | 2024 | 41680 | 1.520 |
Why?
|
Heart Defects, Congenital | 16 | 2024 | 4712 | 1.470 |
Why?
|
Nursing Homes | 7 | 2015 | 1084 | 1.440 |
Why?
|
Databases, Factual | 30 | 2024 | 8060 | 1.430 |
Why?
|
Prescription Drugs | 8 | 2024 | 634 | 1.420 |
Why?
|
Pharmacoepidemiology | 8 | 2020 | 351 | 1.380 |
Why?
|
Amphetamine | 4 | 2024 | 222 | 1.370 |
Why?
|
Warfarin | 7 | 2020 | 1494 | 1.370 |
Why?
|
Drug Utilization | 11 | 2019 | 1187 | 1.350 |
Why?
|
Pre-Eclampsia | 7 | 2024 | 1257 | 1.340 |
Why?
|
Placenta Diseases | 2 | 2022 | 199 | 1.320 |
Why?
|
Buprenorphine | 4 | 2024 | 665 | 1.280 |
Why?
|
Congenital Abnormalities | 6 | 2024 | 704 | 1.260 |
Why?
|
Pregnancy Complications, Infectious | 7 | 2022 | 2184 | 1.250 |
Why?
|
Pregnancy Outcome | 15 | 2024 | 2969 | 1.180 |
Why?
|
United States | 107 | 2024 | 72909 | 1.180 |
Why?
|
Premature Birth | 9 | 2024 | 1830 | 1.130 |
Why?
|
Infant, Newborn | 44 | 2024 | 26380 | 1.080 |
Why?
|
Female | 182 | 2024 | 396141 | 1.050 |
Why?
|
Metformin | 6 | 2024 | 904 | 1.050 |
Why?
|
Oxytocics | 3 | 2015 | 67 | 1.050 |
Why?
|
Uterine Inertia | 3 | 2015 | 29 | 1.010 |
Why?
|
Attention Deficit Disorder with Hyperactivity | 5 | 2024 | 3719 | 1.010 |
Why?
|
Anticoagulants | 7 | 2020 | 4856 | 0.990 |
Why?
|
Persistent Fetal Circulation Syndrome | 2 | 2015 | 80 | 0.960 |
Why?
|
Parturition | 3 | 2022 | 453 | 0.890 |
Why?
|
Abruptio Placentae | 3 | 2022 | 116 | 0.880 |
Why?
|
Mood Disorders | 3 | 2020 | 1127 | 0.870 |
Why?
|
Anticonvulsants | 7 | 2024 | 1919 | 0.850 |
Why?
|
Humans | 216 | 2024 | 765926 | 0.850 |
Why?
|
Product Surveillance, Postmarketing | 4 | 2021 | 463 | 0.840 |
Why?
|
Clubfoot | 1 | 2024 | 87 | 0.840 |
Why?
|
Young Adult | 64 | 2024 | 59857 | 0.820 |
Why?
|
Adult | 111 | 2024 | 223088 | 0.810 |
Why?
|
Prenatal Care | 4 | 2020 | 1158 | 0.790 |
Why?
|
Gastroschisis | 1 | 2023 | 99 | 0.780 |
Why?
|
Comparative Effectiveness Research | 4 | 2019 | 713 | 0.780 |
Why?
|
Neural Tube Defects | 1 | 2024 | 256 | 0.760 |
Why?
|
Maternal Exposure | 3 | 2020 | 1098 | 0.760 |
Why?
|
Live Birth | 3 | 2022 | 516 | 0.750 |
Why?
|
Foramen Ovale, Patent | 1 | 2024 | 209 | 0.740 |
Why?
|
Cleft Palate | 4 | 2020 | 596 | 0.740 |
Why?
|
Heart Septal Defects, Ventricular | 1 | 2024 | 477 | 0.730 |
Why?
|
Abortion, Spontaneous | 2 | 2023 | 536 | 0.730 |
Why?
|
Azabicyclo Compounds | 1 | 2021 | 66 | 0.720 |
Why?
|
Risk | 17 | 2021 | 9599 | 0.720 |
Why?
|
Insurance Claim Review | 5 | 2020 | 744 | 0.700 |
Why?
|
Candidiasis, Vulvovaginal | 1 | 2020 | 25 | 0.690 |
Why?
|
Psychotropic Drugs | 4 | 2024 | 880 | 0.690 |
Why?
|
Data Mining | 3 | 2021 | 559 | 0.690 |
Why?
|
Hydroxychloroquine | 3 | 2021 | 429 | 0.680 |
Why?
|
Vomiting | 2 | 2020 | 646 | 0.670 |
Why?
|
Anti-Bacterial Agents | 7 | 2024 | 7473 | 0.670 |
Why?
|
Fluconazole | 1 | 2020 | 154 | 0.660 |
Why?
|
Narcotic Antagonists | 1 | 2024 | 590 | 0.660 |
Why?
|
Homes for the Aged | 2 | 2012 | 273 | 0.650 |
Why?
|
Acetamides | 1 | 2021 | 260 | 0.650 |
Why?
|
Nausea | 2 | 2020 | 678 | 0.640 |
Why?
|
Tramadol | 3 | 2024 | 63 | 0.640 |
Why?
|
Adolescent | 51 | 2024 | 88811 | 0.640 |
Why?
|
Quinolones | 1 | 2022 | 387 | 0.630 |
Why?
|
Central Nervous System Stimulants | 3 | 2024 | 1166 | 0.630 |
Why?
|
Infant, Newborn, Diseases | 3 | 2022 | 587 | 0.620 |
Why?
|
Haloperidol | 2 | 2018 | 394 | 0.610 |
Why?
|
Stillbirth | 5 | 2024 | 381 | 0.590 |
Why?
|
Depression | 6 | 2024 | 8223 | 0.590 |
Why?
|
Postpartum Hemorrhage | 6 | 2020 | 275 | 0.580 |
Why?
|
Diabetes Mellitus, Type 2 | 11 | 2024 | 12235 | 0.570 |
Why?
|
Infant, Small for Gestational Age | 5 | 2024 | 468 | 0.560 |
Why?
|
Adrenergic beta-Antagonists | 3 | 2019 | 1238 | 0.560 |
Why?
|
Depressive Disorder | 3 | 2014 | 3712 | 0.550 |
Why?
|
Methadone | 5 | 2024 | 318 | 0.550 |
Why?
|
Cleft Lip | 2 | 2020 | 512 | 0.540 |
Why?
|
Hypoglycemic Agents | 10 | 2024 | 3106 | 0.530 |
Why?
|
Dementia | 5 | 2015 | 2741 | 0.520 |
Why?
|
Insurance, Health | 8 | 2024 | 2520 | 0.520 |
Why?
|
Investments | 1 | 2017 | 148 | 0.500 |
Why?
|
Administration, Oral | 6 | 2020 | 4016 | 0.490 |
Why?
|
Child | 32 | 2024 | 80568 | 0.490 |
Why?
|
Atrial Fibrillation | 6 | 2020 | 5186 | 0.490 |
Why?
|
Antifungal Agents | 1 | 2020 | 769 | 0.480 |
Why?
|
Diabetes, Gestational | 3 | 2021 | 1263 | 0.480 |
Why?
|
Lithium Compounds | 3 | 2024 | 226 | 0.480 |
Why?
|
Bacterial Infections | 1 | 2023 | 1387 | 0.470 |
Why?
|
Bradycardia | 1 | 2016 | 304 | 0.460 |
Why?
|
Research Design | 6 | 2019 | 6204 | 0.460 |
Why?
|
Prevalence | 19 | 2024 | 15828 | 0.460 |
Why?
|
Clinical Coding | 1 | 2016 | 187 | 0.460 |
Why?
|
Stroke | 13 | 2020 | 9739 | 0.460 |
Why?
|
Contraception Behavior | 2 | 2020 | 185 | 0.450 |
Why?
|
Benzodiazepines | 3 | 2017 | 1136 | 0.450 |
Why?
|
Hospitalization | 12 | 2021 | 10810 | 0.440 |
Why?
|
Epidemiology | 1 | 2016 | 278 | 0.430 |
Why?
|
Nutrition Surveys | 2 | 2023 | 1735 | 0.430 |
Why?
|
Pharmaceutical Preparations | 2 | 2021 | 1084 | 0.430 |
Why?
|
Risk Assessment | 14 | 2022 | 24275 | 0.430 |
Why?
|
Antirheumatic Agents | 2 | 2021 | 1378 | 0.430 |
Why?
|
Acute Disease | 6 | 2024 | 7236 | 0.420 |
Why?
|
Psychotic Disorders | 3 | 2018 | 3274 | 0.420 |
Why?
|
Risk Factors | 32 | 2024 | 74850 | 0.420 |
Why?
|
Piperazines | 2 | 2021 | 2546 | 0.420 |
Why?
|
Pregnancy Complications, Cardiovascular | 5 | 2024 | 518 | 0.420 |
Why?
|
Hypnotics and Sedatives | 1 | 2021 | 1192 | 0.420 |
Why?
|
Terminally Ill | 1 | 2015 | 240 | 0.410 |
Why?
|
Tumor Necrosis Factor-alpha | 1 | 2024 | 4342 | 0.410 |
Why?
|
Antihypertensive Agents | 8 | 2024 | 2028 | 0.400 |
Why?
|
Insurance Benefits | 1 | 2014 | 186 | 0.400 |
Why?
|
Angiotensin-Converting Enzyme Inhibitors | 2 | 2017 | 1513 | 0.400 |
Why?
|
Middle Aged | 60 | 2024 | 223016 | 0.390 |
Why?
|
Comorbidity | 6 | 2021 | 10575 | 0.380 |
Why?
|
Male | 67 | 2024 | 363815 | 0.380 |
Why?
|
Bipolar Disorder | 4 | 2024 | 5128 | 0.380 |
Why?
|
Drug Therapy, Combination | 5 | 2024 | 6306 | 0.370 |
Why?
|
Risk Adjustment | 1 | 2015 | 596 | 0.370 |
Why?
|
Hydroxymethylglutaryl-CoA Reductase Inhibitors | 2 | 2017 | 3249 | 0.360 |
Why?
|
Antiviral Agents | 3 | 2022 | 3053 | 0.360 |
Why?
|
Mortality | 3 | 2013 | 2910 | 0.360 |
Why?
|
Cost-Benefit Analysis | 6 | 2017 | 5531 | 0.360 |
Why?
|
International Classification of Diseases | 5 | 2024 | 934 | 0.350 |
Why?
|
Polyamines | 2 | 2008 | 132 | 0.350 |
Why?
|
Opiate Substitution Treatment | 3 | 2024 | 452 | 0.340 |
Why?
|
Pain, Postoperative | 5 | 2018 | 1767 | 0.340 |
Why?
|
Gestational Age | 6 | 2024 | 3616 | 0.330 |
Why?
|
Central Nervous System | 1 | 2017 | 1343 | 0.330 |
Why?
|
Risperidone | 3 | 2018 | 383 | 0.320 |
Why?
|
Fertility | 3 | 2020 | 770 | 0.320 |
Why?
|
Aged | 45 | 2024 | 171163 | 0.320 |
Why?
|
Patient Acceptance of Health Care | 3 | 2020 | 3230 | 0.320 |
Why?
|
Economics, Pharmaceutical | 2 | 2009 | 88 | 0.320 |
Why?
|
Hypoglycemia | 1 | 2016 | 896 | 0.320 |
Why?
|
Industry | 1 | 2011 | 362 | 0.310 |
Why?
|
Cause of Death | 2 | 2017 | 3715 | 0.310 |
Why?
|
Pyrimidines | 1 | 2021 | 3049 | 0.310 |
Why?
|
Pregnancy in Diabetics | 3 | 2024 | 198 | 0.310 |
Why?
|
Calcinosis | 3 | 2008 | 1475 | 0.310 |
Why?
|
Calcium Carbonate | 1 | 2008 | 62 | 0.300 |
Why?
|
Hyperphosphatemia | 1 | 2008 | 38 | 0.300 |
Why?
|
Algorithms | 9 | 2024 | 14064 | 0.300 |
Why?
|
Cesarean Section | 4 | 2024 | 1418 | 0.300 |
Why?
|
Outpatients | 4 | 2023 | 1595 | 0.300 |
Why?
|
Fetal Growth Retardation | 3 | 2022 | 591 | 0.290 |
Why?
|
Hospital Mortality | 2 | 2018 | 5339 | 0.270 |
Why?
|
Chelating Agents | 1 | 2008 | 380 | 0.270 |
Why?
|
Pregnant Women | 3 | 2021 | 576 | 0.270 |
Why?
|
Aged, 80 and over | 18 | 2022 | 59496 | 0.270 |
Why?
|
Epidemiologic Studies | 1 | 2010 | 677 | 0.260 |
Why?
|
Logistic Models | 9 | 2018 | 13273 | 0.260 |
Why?
|
Case-Control Studies | 7 | 2021 | 22228 | 0.260 |
Why?
|
Research Personnel | 1 | 2011 | 589 | 0.260 |
Why?
|
Mental Disorders | 4 | 2024 | 6870 | 0.260 |
Why?
|
Phosphorus Metabolism Disorders | 1 | 2005 | 9 | 0.250 |
Why?
|
Hemorrhage | 4 | 2020 | 3466 | 0.250 |
Why?
|
Renal Dialysis | 2 | 2005 | 1791 | 0.250 |
Why?
|
Pregnancy Trimesters | 2 | 2017 | 197 | 0.250 |
Why?
|
Infant | 12 | 2024 | 36426 | 0.240 |
Why?
|
Epoxy Compounds | 1 | 2005 | 137 | 0.240 |
Why?
|
United States Food and Drug Administration | 5 | 2024 | 1673 | 0.240 |
Why?
|
Patient Compliance | 4 | 2020 | 2693 | 0.240 |
Why?
|
Delivery of Health Care | 2 | 2022 | 5364 | 0.240 |
Why?
|
Hypertension | 8 | 2024 | 8616 | 0.240 |
Why?
|
Fathers | 2 | 2024 | 377 | 0.230 |
Why?
|
Epidemiologic Methods | 4 | 2013 | 1325 | 0.230 |
Why?
|
Teratogens | 2 | 2023 | 120 | 0.230 |
Why?
|
Pyridones | 2 | 2020 | 816 | 0.230 |
Why?
|
Phenylpropionates | 1 | 2024 | 34 | 0.230 |
Why?
|
Proportional Hazards Models | 7 | 2022 | 12529 | 0.230 |
Why?
|
Follow-Up Studies | 12 | 2021 | 39228 | 0.220 |
Why?
|
Prescriptions | 4 | 2022 | 388 | 0.220 |
Why?
|
Hepatitis C, Chronic | 2 | 2022 | 1032 | 0.220 |
Why?
|
Dextroamphetamine | 1 | 2024 | 132 | 0.220 |
Why?
|
Chlorprothixene | 1 | 2023 | 3 | 0.210 |
Why?
|
Residence Characteristics | 2 | 2013 | 2116 | 0.210 |
Why?
|
Pain | 5 | 2022 | 5077 | 0.210 |
Why?
|
Polyethylenes | 1 | 2005 | 289 | 0.210 |
Why?
|
Pregnancy Trimester, Second | 2 | 2024 | 737 | 0.210 |
Why?
|
Birth Certificates | 1 | 2022 | 71 | 0.200 |
Why?
|
Placenta | 2 | 2022 | 1726 | 0.200 |
Why?
|
Liver Function Tests | 1 | 2024 | 527 | 0.200 |
Why?
|
Pyridazines | 1 | 2024 | 200 | 0.200 |
Why?
|
Time Factors | 11 | 2024 | 40097 | 0.200 |
Why?
|
Infant, Low Birth Weight | 2 | 2024 | 870 | 0.200 |
Why?
|
Delivery, Obstetric | 4 | 2020 | 947 | 0.200 |
Why?
|
Quality Indicators, Health Care | 1 | 2012 | 1804 | 0.200 |
Why?
|
Cardiotonic Agents | 1 | 2005 | 539 | 0.200 |
Why?
|
Models, Statistical | 5 | 2021 | 5088 | 0.200 |
Why?
|
Statistics as Topic | 3 | 2018 | 2350 | 0.190 |
Why?
|
Models, Economic | 3 | 2008 | 716 | 0.190 |
Why?
|
Hypertension, Pregnancy-Induced | 3 | 2024 | 530 | 0.190 |
Why?
|
Anti-Asthmatic Agents | 2 | 2024 | 572 | 0.190 |
Why?
|
Meta-Analysis as Topic | 1 | 2006 | 1366 | 0.190 |
Why?
|
Tetanus | 1 | 2021 | 51 | 0.190 |
Why?
|
Biological Products | 2 | 2024 | 947 | 0.190 |
Why?
|
Diphtheria | 1 | 2021 | 32 | 0.190 |
Why?
|
Insurance | 1 | 2023 | 115 | 0.190 |
Why?
|
Epilepsy, Generalized | 1 | 2023 | 182 | 0.190 |
Why?
|
Calcium Channel Blockers | 2 | 2015 | 685 | 0.180 |
Why?
|
Budgets | 2 | 2017 | 232 | 0.180 |
Why?
|
For-Profit Insurance Plans | 1 | 2020 | 8 | 0.180 |
Why?
|
Whooping Cough | 1 | 2021 | 87 | 0.180 |
Why?
|
Drug Combinations | 2 | 2024 | 2075 | 0.180 |
Why?
|
Drug Labeling | 2 | 2024 | 251 | 0.170 |
Why?
|
Managed Care Programs | 1 | 2005 | 934 | 0.170 |
Why?
|
Mycoses | 1 | 2023 | 389 | 0.170 |
Why?
|
Retrospective Studies | 16 | 2024 | 81537 | 0.170 |
Why?
|
Pregnancy Trimester, Third | 4 | 2015 | 587 | 0.170 |
Why?
|
Myocardial Infarction | 3 | 2018 | 11508 | 0.170 |
Why?
|
Ozone | 1 | 2024 | 499 | 0.170 |
Why?
|
Analgesia, Obstetrical | 1 | 2021 | 169 | 0.170 |
Why?
|
Dipeptidyl-Peptidase IV Inhibitors | 1 | 2024 | 317 | 0.160 |
Why?
|
Hydrocodone | 2 | 2022 | 48 | 0.160 |
Why?
|
Labetalol | 2 | 2016 | 29 | 0.160 |
Why?
|
Child, Hospitalized | 1 | 2021 | 181 | 0.160 |
Why?
|
Codeine | 2 | 2022 | 52 | 0.160 |
Why?
|
Contraceptive Agents, Female | 1 | 2020 | 122 | 0.160 |
Why?
|
Birth Rate | 1 | 2020 | 168 | 0.160 |
Why?
|
Pyrazoles | 2 | 2020 | 2031 | 0.160 |
Why?
|
Lithium | 2 | 2024 | 599 | 0.160 |
Why?
|
Dibenzothiazepines | 2 | 2012 | 101 | 0.160 |
Why?
|
Musculoskeletal Abnormalities | 1 | 2020 | 101 | 0.160 |
Why?
|
Hepatitis C | 2 | 2022 | 1596 | 0.160 |
Why?
|
Data Interpretation, Statistical | 3 | 2020 | 2688 | 0.160 |
Why?
|
Kidney Failure, Chronic | 3 | 2008 | 2504 | 0.160 |
Why?
|
Insulin | 5 | 2024 | 6603 | 0.160 |
Why?
|
Confidence Intervals | 2 | 2015 | 2915 | 0.160 |
Why?
|
Osteoporosis | 2 | 2005 | 1582 | 0.160 |
Why?
|
Thalidomide | 1 | 2024 | 886 | 0.160 |
Why?
|
European Union | 1 | 2019 | 157 | 0.150 |
Why?
|
Cardiovascular Abnormalities | 1 | 2019 | 148 | 0.150 |
Why?
|
Drug Interactions | 2 | 2020 | 1416 | 0.150 |
Why?
|
DiGeorge Syndrome | 1 | 2020 | 187 | 0.150 |
Why?
|
Reverse Transcriptase Inhibitors | 1 | 2021 | 618 | 0.150 |
Why?
|
Prospective Studies | 11 | 2023 | 54807 | 0.150 |
Why?
|
Asthma | 3 | 2024 | 6268 | 0.150 |
Why?
|
Analgesics | 3 | 2024 | 1057 | 0.150 |
Why?
|
Health Planning | 1 | 2019 | 233 | 0.150 |
Why?
|
Veterans | 2 | 2022 | 2667 | 0.150 |
Why?
|
Israel | 3 | 2024 | 729 | 0.150 |
Why?
|
Epilepsy | 3 | 2024 | 3317 | 0.150 |
Why?
|
Isotretinoin | 1 | 2019 | 135 | 0.150 |
Why?
|
Epidemiologic Research Design | 1 | 2021 | 368 | 0.140 |
Why?
|
Internet | 1 | 2010 | 3106 | 0.140 |
Why?
|
Abortion, Induced | 1 | 2023 | 471 | 0.140 |
Why?
|
Injections, Intravenous | 1 | 2020 | 1376 | 0.140 |
Why?
|
Medical Records | 1 | 2023 | 1408 | 0.140 |
Why?
|
Substance Withdrawal Syndrome | 1 | 2022 | 627 | 0.140 |
Why?
|
Maternal Age | 2 | 2023 | 804 | 0.140 |
Why?
|
Perinatal Care | 1 | 2020 | 243 | 0.140 |
Why?
|
Infertility, Male | 1 | 2020 | 395 | 0.140 |
Why?
|
Registries | 5 | 2018 | 8346 | 0.140 |
Why?
|
Computer Simulation | 4 | 2020 | 6251 | 0.140 |
Why?
|
Oocyte Retrieval | 1 | 2018 | 162 | 0.140 |
Why?
|
Treatment Failure | 1 | 2023 | 2653 | 0.140 |
Why?
|
Drug Utilization Review | 1 | 2018 | 248 | 0.140 |
Why?
|
Probability | 2 | 2019 | 2474 | 0.140 |
Why?
|
Healthcare Disparities | 1 | 2012 | 3407 | 0.130 |
Why?
|
Vascular Diseases | 1 | 2005 | 1161 | 0.130 |
Why?
|
Microcephaly | 1 | 2020 | 427 | 0.130 |
Why?
|
Gastrointestinal Agents | 1 | 2021 | 511 | 0.130 |
Why?
|
Adrenergic Uptake Inhibitors | 1 | 2017 | 187 | 0.130 |
Why?
|
Drug Substitution | 1 | 2019 | 292 | 0.130 |
Why?
|
Tretinoin | 1 | 2019 | 524 | 0.130 |
Why?
|
Atenolol | 1 | 2016 | 99 | 0.130 |
Why?
|
Office Visits | 1 | 2020 | 594 | 0.130 |
Why?
|
Incidence | 6 | 2021 | 21513 | 0.130 |
Why?
|
Metoprolol | 1 | 2016 | 90 | 0.130 |
Why?
|
Medication Adherence | 2 | 2020 | 2190 | 0.130 |
Why?
|
Predictive Value of Tests | 3 | 2023 | 15401 | 0.130 |
Why?
|
Hyperglycemia | 1 | 2024 | 1389 | 0.130 |
Why?
|
Morphine | 2 | 2022 | 660 | 0.130 |
Why?
|
Odds Ratio | 5 | 2018 | 9656 | 0.130 |
Why?
|
Severity of Illness Index | 4 | 2019 | 15878 | 0.130 |
Why?
|
Inappropriate Prescribing | 1 | 2018 | 211 | 0.130 |
Why?
|
Particulate Matter | 2 | 2024 | 2623 | 0.130 |
Why?
|
Pandemics | 4 | 2023 | 8721 | 0.120 |
Why?
|
Puerperal Disorders | 1 | 2018 | 304 | 0.120 |
Why?
|
Vaccination | 3 | 2023 | 3430 | 0.120 |
Why?
|
Zidovudine | 1 | 2017 | 626 | 0.120 |
Why?
|
Antidepressive Agents, Tricyclic | 2 | 2014 | 427 | 0.120 |
Why?
|
Advisory Committees | 1 | 2019 | 796 | 0.120 |
Why?
|
Cost of Illness | 4 | 2003 | 1949 | 0.120 |
Why?
|
Blood Glucose | 3 | 2024 | 6422 | 0.120 |
Why?
|
Drug Packaging | 1 | 2014 | 44 | 0.120 |
Why?
|
Patient Simulation | 1 | 2017 | 301 | 0.120 |
Why?
|
Dose-Response Relationship, Drug | 6 | 2022 | 10727 | 0.120 |
Why?
|
Incidental Findings | 1 | 2019 | 698 | 0.120 |
Why?
|
Data Collection | 3 | 2014 | 3318 | 0.120 |
Why?
|
Anxiety | 2 | 2022 | 4669 | 0.120 |
Why?
|
Spondylitis, Ankylosing | 1 | 2016 | 157 | 0.120 |
Why?
|
Autistic Disorder | 1 | 2024 | 1238 | 0.110 |
Why?
|
Papillomavirus Vaccines | 1 | 2020 | 495 | 0.110 |
Why?
|
Drug Therapy | 1 | 2017 | 504 | 0.110 |
Why?
|
Cytomegalovirus Infections | 1 | 2020 | 837 | 0.110 |
Why?
|
Ovarian Neoplasms | 1 | 2011 | 4904 | 0.110 |
Why?
|
Intraoperative Care | 1 | 2018 | 768 | 0.110 |
Why?
|
Treatment Outcome | 11 | 2024 | 65194 | 0.110 |
Why?
|
Stress Disorders, Post-Traumatic | 2 | 2022 | 4627 | 0.110 |
Why?
|
Methylergonovine | 1 | 2013 | 8 | 0.110 |
Why?
|
Reproduction | 1 | 2018 | 645 | 0.110 |
Why?
|
Paternal Exposure | 2 | 2024 | 100 | 0.110 |
Why?
|
Hospitals, Community | 1 | 2016 | 363 | 0.110 |
Why?
|
Anti-HIV Agents | 2 | 2021 | 4558 | 0.110 |
Why?
|
Denmark | 2 | 2020 | 774 | 0.110 |
Why?
|
Clozapine | 1 | 2017 | 509 | 0.110 |
Why?
|
Postoperative Period | 1 | 2018 | 1818 | 0.110 |
Why?
|
Air Pollution | 2 | 2024 | 2380 | 0.110 |
Why?
|
Arthritis, Psoriatic | 1 | 2016 | 218 | 0.110 |
Why?
|
Air Pollutants | 2 | 2024 | 2922 | 0.100 |
Why?
|
Cardiomyopathies | 1 | 2005 | 2068 | 0.100 |
Why?
|
Antimanic Agents | 3 | 2024 | 523 | 0.100 |
Why?
|
Cross-Sectional Studies | 7 | 2024 | 26282 | 0.100 |
Why?
|
Health Status Disparities | 1 | 2024 | 1878 | 0.100 |
Why?
|
Thrombophilia | 1 | 2015 | 308 | 0.100 |
Why?
|
Platelet Aggregation Inhibitors | 1 | 2024 | 2769 | 0.100 |
Why?
|
HIV Infections | 4 | 2021 | 17531 | 0.100 |
Why?
|
Insurance, Pharmaceutical Services | 1 | 2015 | 347 | 0.100 |
Why?
|
Cardiac Surgical Procedures | 2 | 2018 | 3682 | 0.100 |
Why?
|
Multivariate Analysis | 6 | 2016 | 12059 | 0.100 |
Why?
|
Medicare | 4 | 2020 | 6815 | 0.100 |
Why?
|
Propylamines | 1 | 2012 | 161 | 0.090 |
Why?
|
Government Regulation | 1 | 2016 | 525 | 0.090 |
Why?
|
Primary Health Care | 2 | 2019 | 4736 | 0.090 |
Why?
|
Ambulatory Care | 3 | 2018 | 2778 | 0.090 |
Why?
|
Analgesia | 1 | 2016 | 461 | 0.090 |
Why?
|
Medical Assistance | 1 | 2012 | 108 | 0.090 |
Why?
|
Reminder Systems | 1 | 2014 | 388 | 0.090 |
Why?
|
Delirium | 3 | 2018 | 1699 | 0.090 |
Why?
|
Sulfonylurea Compounds | 2 | 2024 | 220 | 0.090 |
Why?
|
Adrenal Cortex Hormones | 2 | 2019 | 1881 | 0.090 |
Why?
|
British Columbia | 1 | 2011 | 238 | 0.090 |
Why?
|
Achievement | 1 | 2012 | 287 | 0.090 |
Why?
|
Anti-Inflammatory Agents, Non-Steroidal | 1 | 2020 | 2270 | 0.090 |
Why?
|
Thiazoles | 1 | 2018 | 1528 | 0.090 |
Why?
|
Child, Preschool | 3 | 2023 | 42510 | 0.090 |
Why?
|
Anesthesia, General | 1 | 2018 | 1182 | 0.090 |
Why?
|
Publication Bias | 1 | 2011 | 157 | 0.090 |
Why?
|
Australia | 3 | 2024 | 1260 | 0.090 |
Why?
|
Germany | 2 | 2024 | 882 | 0.090 |
Why?
|
Evidence-Based Medicine | 2 | 2019 | 3690 | 0.090 |
Why?
|
Tobacco Use Disorder | 1 | 2016 | 708 | 0.090 |
Why?
|
Linear Models | 3 | 2017 | 5873 | 0.090 |
Why?
|
Longitudinal Studies | 3 | 2024 | 14745 | 0.080 |
Why?
|
Fetal Diseases | 1 | 2015 | 915 | 0.080 |
Why?
|
beta-Thalassemia | 2 | 2002 | 233 | 0.080 |
Why?
|
Blood Transfusion | 1 | 2016 | 1307 | 0.080 |
Why?
|
Colitis, Ulcerative | 1 | 2021 | 1912 | 0.080 |
Why?
|
Chronic Disease | 3 | 2024 | 9351 | 0.080 |
Why?
|
Crohn Disease | 1 | 2021 | 2281 | 0.080 |
Why?
|
Mental Health | 1 | 2023 | 3272 | 0.080 |
Why?
|
Inpatients | 3 | 2016 | 2563 | 0.080 |
Why?
|
Papillomavirus Infections | 1 | 2020 | 1637 | 0.080 |
Why?
|
Chi-Square Distribution | 1 | 2014 | 3430 | 0.080 |
Why?
|
Income | 1 | 2017 | 1874 | 0.080 |
Why?
|
Patient Discharge | 2 | 2018 | 3460 | 0.080 |
Why?
|
Prognosis | 5 | 2019 | 29890 | 0.080 |
Why?
|
Immunosuppressive Agents | 2 | 2021 | 4213 | 0.070 |
Why?
|
Perioperative Care | 1 | 2016 | 1042 | 0.070 |
Why?
|
Acetaminophen | 2 | 2023 | 549 | 0.070 |
Why?
|
Life Style | 1 | 2019 | 3928 | 0.070 |
Why?
|
Greece | 1 | 2008 | 341 | 0.070 |
Why?
|
Menstrual Cycle | 1 | 2011 | 539 | 0.070 |
Why?
|
Cross-Over Studies | 2 | 2024 | 2108 | 0.070 |
Why?
|
Sweden | 2 | 2021 | 1381 | 0.070 |
Why?
|
Sensitivity and Specificity | 2 | 2020 | 14643 | 0.070 |
Why?
|
Smoking | 3 | 2019 | 9082 | 0.070 |
Why?
|
Societies, Medical | 1 | 2019 | 3953 | 0.070 |
Why?
|
Femoral Fractures | 1 | 2011 | 375 | 0.070 |
Why?
|
Cardiovascular Diseases | 3 | 2008 | 15645 | 0.070 |
Why?
|
Canada | 3 | 2008 | 2120 | 0.070 |
Why?
|
Immunologic Factors | 1 | 2016 | 1590 | 0.070 |
Why?
|
Respiration, Artificial | 1 | 2018 | 2726 | 0.070 |
Why?
|
Kaplan-Meier Estimate | 2 | 2020 | 6503 | 0.060 |
Why?
|
Calcium Compounds | 1 | 2005 | 40 | 0.060 |
Why?
|
Regression Analysis | 2 | 2005 | 6321 | 0.060 |
Why?
|
Direct Service Costs | 1 | 2005 | 61 | 0.060 |
Why?
|
Arthroplasty, Replacement, Hip | 1 | 2016 | 1414 | 0.060 |
Why?
|
Arthroplasty, Replacement, Knee | 1 | 2016 | 1378 | 0.060 |
Why?
|
Liver Cirrhosis | 1 | 2016 | 1961 | 0.060 |
Why?
|
Health Care Costs | 3 | 2006 | 3241 | 0.060 |
Why?
|
Kidney Diseases | 1 | 2016 | 2100 | 0.060 |
Why?
|
Electronic Health Records | 2 | 2021 | 4863 | 0.060 |
Why?
|
Deferoxamine | 2 | 2002 | 154 | 0.060 |
Why?
|
Autoimmune Diseases | 1 | 2017 | 2248 | 0.060 |
Why?
|
Embolism | 2 | 2020 | 401 | 0.060 |
Why?
|
Sex Reassignment Procedures | 1 | 2024 | 72 | 0.060 |
Why?
|
Acetates | 1 | 2005 | 314 | 0.060 |
Why?
|
Time | 1 | 2005 | 549 | 0.050 |
Why?
|
Breast Neoplasms | 1 | 2011 | 21069 | 0.050 |
Why?
|
Lupus Erythematosus, Systemic | 1 | 2016 | 2157 | 0.050 |
Why?
|
Poverty | 1 | 2015 | 2714 | 0.050 |
Why?
|
Taiwan | 1 | 2024 | 521 | 0.050 |
Why?
|
Fertilization | 1 | 2024 | 197 | 0.050 |
Why?
|
Spermatogenesis | 1 | 2024 | 259 | 0.050 |
Why?
|
Length of Stay | 5 | 2017 | 6486 | 0.050 |
Why?
|
Coronavirus Infections | 1 | 2020 | 3109 | 0.050 |
Why?
|
Bayes Theorem | 1 | 2011 | 2353 | 0.050 |
Why?
|
Fractures, Bone | 2 | 2005 | 2041 | 0.050 |
Why?
|
Mifepristone | 1 | 2023 | 150 | 0.050 |
Why?
|
Pneumonia, Viral | 1 | 2020 | 3231 | 0.050 |
Why?
|
Substance-Related Disorders | 2 | 2016 | 4418 | 0.050 |
Why?
|
Republic of Korea | 1 | 2024 | 583 | 0.050 |
Why?
|
Randomized Controlled Trials as Topic | 5 | 2022 | 10380 | 0.050 |
Why?
|
Seizures | 1 | 2015 | 2997 | 0.050 |
Why?
|
Pravastatin | 2 | 2003 | 391 | 0.050 |
Why?
|
Socioeconomic Factors | 3 | 2024 | 7842 | 0.050 |
Why?
|
Recurrence | 3 | 2018 | 8492 | 0.050 |
Why?
|
Hydromorphone | 1 | 2022 | 70 | 0.050 |
Why?
|
Guideline Adherence | 1 | 2012 | 2234 | 0.050 |
Why?
|
Anxiety Disorders | 1 | 2013 | 2739 | 0.050 |
Why?
|
Postpartum Period | 2 | 2023 | 1195 | 0.050 |
Why?
|
Aminosalicylic Acid | 1 | 2021 | 20 | 0.050 |
Why?
|
Phosphates | 1 | 2005 | 763 | 0.050 |
Why?
|
Age Factors | 6 | 2020 | 18382 | 0.050 |
Why?
|
Models, Biological | 1 | 2018 | 9443 | 0.050 |
Why?
|
Quality-Adjusted Life Years | 2 | 2005 | 1740 | 0.050 |
Why?
|
Sulfasalazine | 1 | 2021 | 85 | 0.050 |
Why?
|
Practice Guidelines as Topic | 2 | 2012 | 7423 | 0.050 |
Why?
|
Disability Evaluation | 1 | 2008 | 1820 | 0.050 |
Why?
|
Iron Chelating Agents | 1 | 2002 | 141 | 0.050 |
Why?
|
Oxycodone | 1 | 2022 | 144 | 0.050 |
Why?
|
Transsexualism | 1 | 2024 | 210 | 0.050 |
Why?
|
Nitrogen Dioxide | 1 | 2024 | 538 | 0.040 |
Why?
|
Monte Carlo Method | 3 | 2015 | 1238 | 0.040 |
Why?
|
Arthritis, Rheumatoid | 1 | 2016 | 3743 | 0.040 |
Why?
|
New South Wales | 1 | 2020 | 69 | 0.040 |
Why?
|
Acute Coronary Syndrome | 1 | 2013 | 2185 | 0.040 |
Why?
|
Sex Factors | 4 | 2020 | 10611 | 0.040 |
Why?
|
Naproxen | 1 | 2020 | 99 | 0.040 |
Why?
|
Sertraline | 1 | 2021 | 209 | 0.040 |
Why?
|
Schizophrenia | 1 | 2019 | 6971 | 0.040 |
Why?
|
Hong Kong | 1 | 2020 | 169 | 0.040 |
Why?
|
Sexual Behavior | 1 | 2010 | 2192 | 0.040 |
Why?
|
Health Care Rationing | 1 | 2003 | 435 | 0.040 |
Why?
|
Reproductive Techniques, Assisted | 1 | 2024 | 503 | 0.040 |
Why?
|
Family Relations | 1 | 2002 | 318 | 0.040 |
Why?
|
Obesity | 2 | 2019 | 13082 | 0.040 |
Why?
|
Continuity of Patient Care | 1 | 2006 | 1075 | 0.040 |
Why?
|
Ibuprofen | 1 | 2020 | 228 | 0.040 |
Why?
|
Hormone Replacement Therapy | 1 | 2024 | 752 | 0.040 |
Why?
|
Environmental Exposure | 2 | 2024 | 4544 | 0.040 |
Why?
|
Decision Making, Organizational | 1 | 2019 | 136 | 0.040 |
Why?
|
International Agencies | 1 | 2019 | 241 | 0.040 |
Why?
|
Quality of Health Care | 1 | 2014 | 4305 | 0.040 |
Why?
|
Norway | 1 | 2020 | 499 | 0.040 |
Why?
|
Finland | 1 | 2020 | 608 | 0.040 |
Why?
|
Feasibility Studies | 1 | 2010 | 5300 | 0.040 |
Why?
|
Preventive Health Services | 1 | 2003 | 570 | 0.040 |
Why?
|
Temperature | 1 | 2024 | 2226 | 0.040 |
Why?
|
Patient Selection | 1 | 2010 | 4248 | 0.040 |
Why?
|
Reproducibility of Results | 2 | 2013 | 20133 | 0.040 |
Why?
|
Spain | 1 | 2019 | 483 | 0.040 |
Why?
|
Long-Term Care | 1 | 2002 | 630 | 0.040 |
Why?
|
Age Distribution | 1 | 2023 | 2864 | 0.030 |
Why?
|
Anticholesteremic Agents | 2 | 2003 | 970 | 0.030 |
Why?
|
Drug and Narcotic Control | 1 | 2018 | 144 | 0.030 |
Why?
|
Italy | 1 | 2019 | 851 | 0.030 |
Why?
|
Quality Improvement | 1 | 2012 | 3847 | 0.030 |
Why?
|
Cytomegalovirus | 1 | 2020 | 753 | 0.030 |
Why?
|
Pregnancy Rate | 1 | 2019 | 654 | 0.030 |
Why?
|
Postoperative Complications | 1 | 2018 | 15802 | 0.030 |
Why?
|
Neonatal Screening | 1 | 2020 | 619 | 0.030 |
Why?
|
Policy Making | 1 | 2019 | 546 | 0.030 |
Why?
|
Survival Analysis | 1 | 2008 | 10086 | 0.030 |
Why?
|
Tidal Volume | 1 | 2018 | 519 | 0.030 |
Why?
|
Health Services | 1 | 2020 | 756 | 0.030 |
Why?
|
Triazines | 1 | 2017 | 307 | 0.030 |
Why?
|
Hepacivirus | 1 | 2022 | 1343 | 0.030 |
Why?
|
Health Care Surveys | 1 | 2002 | 2426 | 0.030 |
Why?
|
Brain Ischemia | 2 | 2015 | 3000 | 0.030 |
Why?
|
Diagnosis-Related Groups | 1 | 2016 | 445 | 0.030 |
Why?
|
Drug Evaluation | 1 | 2015 | 642 | 0.030 |
Why?
|
Methyldopa | 1 | 2013 | 18 | 0.030 |
Why?
|
Primary Prevention | 2 | 2018 | 1187 | 0.030 |
Why?
|
Costs and Cost Analysis | 1 | 1999 | 1666 | 0.030 |
Why?
|
Insurance Coverage | 2 | 2015 | 1945 | 0.030 |
Why?
|
Policy | 1 | 2017 | 512 | 0.030 |
Why?
|
Hospital Costs | 1 | 1999 | 955 | 0.030 |
Why?
|
Obstetrics | 1 | 2020 | 679 | 0.030 |
Why?
|
Heart Rate | 1 | 2005 | 4203 | 0.030 |
Why?
|
Hypertension, Pulmonary | 1 | 2024 | 1604 | 0.030 |
Why?
|
Positive-Pressure Respiration | 1 | 2018 | 712 | 0.030 |
Why?
|
Electrocardiography | 1 | 2006 | 6409 | 0.030 |
Why?
|
HIV | 1 | 2020 | 1587 | 0.030 |
Why?
|
Electronics | 1 | 2014 | 314 | 0.030 |
Why?
|
Disseminated Intravascular Coagulation | 1 | 2013 | 186 | 0.030 |
Why?
|
Polypharmacy | 1 | 2015 | 306 | 0.030 |
Why?
|
Language Arts | 1 | 2012 | 2 | 0.030 |
Why?
|
Infertility, Female | 1 | 2018 | 763 | 0.030 |
Why?
|
Iceland | 1 | 2012 | 183 | 0.020 |
Why?
|
Back Pain | 1 | 2016 | 546 | 0.020 |
Why?
|
Family | 1 | 2023 | 3208 | 0.020 |
Why?
|
Internationality | 1 | 2017 | 1007 | 0.020 |
Why?
|
Ultrasonography | 1 | 2005 | 5987 | 0.020 |
Why?
|
Maternal Health Services | 1 | 2017 | 472 | 0.020 |
Why?
|
Infant, Premature | 1 | 2021 | 2121 | 0.020 |
Why?
|
Secondary Prevention | 1 | 2018 | 1470 | 0.020 |
Why?
|
Ultrasonography, Prenatal | 1 | 2019 | 1772 | 0.020 |
Why?
|
Thromboembolism | 1 | 2018 | 1001 | 0.020 |
Why?
|
Mathematics | 1 | 2012 | 696 | 0.020 |
Why?
|
Quality of Life | 3 | 2009 | 13463 | 0.020 |
Why?
|
Mothers | 1 | 2021 | 2206 | 0.020 |
Why?
|
Health Expenditures | 1 | 2003 | 2388 | 0.020 |
Why?
|
Forecasting | 1 | 1999 | 2936 | 0.020 |
Why?
|
Glucose | 1 | 2021 | 4335 | 0.020 |
Why?
|
Interviews as Topic | 1 | 2017 | 2740 | 0.020 |
Why?
|
Blood Pressure | 1 | 2005 | 8530 | 0.020 |
Why?
|
Aspirin | 1 | 2020 | 3135 | 0.020 |
Why?
|
Clinical Trials as Topic | 2 | 2019 | 8037 | 0.020 |
Why?
|
Genotype | 1 | 2022 | 13026 | 0.020 |
Why?
|
Massachusetts | 1 | 2021 | 8882 | 0.020 |
Why?
|
Boston | 1 | 2020 | 9334 | 0.020 |
Why?
|
Medical Informatics | 1 | 2014 | 743 | 0.020 |
Why?
|
Multiple Myeloma | 1 | 2024 | 5189 | 0.020 |
Why?
|
Coronary Disease | 1 | 2000 | 5919 | 0.020 |
Why?
|
Educational Measurement | 1 | 2012 | 1260 | 0.020 |
Why?
|
Patient Protection and Affordable Care Act | 1 | 2015 | 1188 | 0.010 |
Why?
|
Saskatchewan | 1 | 2004 | 8 | 0.010 |
Why?
|
Software | 1 | 2018 | 4462 | 0.010 |
Why?
|
Cerebral Hemorrhage | 1 | 2015 | 2649 | 0.010 |
Why?
|
Migraine Disorders | 1 | 2016 | 1729 | 0.010 |
Why?
|
Disease Progression | 1 | 2019 | 13614 | 0.010 |
Why?
|
Chelation Therapy | 1 | 2002 | 76 | 0.010 |
Why?
|
Scotland | 1 | 2000 | 141 | 0.010 |
Why?
|
Belgium | 1 | 2000 | 119 | 0.010 |
Why?
|
Sepsis | 1 | 2013 | 2603 | 0.010 |
Why?
|
Iron Overload | 1 | 2002 | 245 | 0.010 |
Why?
|
Endocrine System Diseases | 1 | 2002 | 244 | 0.010 |
Why?
|
Drug Costs | 1 | 2006 | 1194 | 0.010 |
Why?
|
Thyroid Diseases | 1 | 2002 | 385 | 0.010 |
Why?
|
Cost Savings | 1 | 2003 | 900 | 0.010 |
Why?
|
Health Status Indicators | 1 | 2003 | 967 | 0.010 |
Why?
|
National Health Programs | 1 | 2001 | 443 | 0.010 |
Why?
|
Demography | 1 | 2001 | 1640 | 0.010 |
Why?
|
Health Services Research | 1 | 2003 | 1811 | 0.010 |
Why?
|
Diabetes Complications | 1 | 2002 | 1318 | 0.010 |
Why?
|
Europe | 1 | 2001 | 3430 | 0.010 |
Why?
|
International Cooperation | 1 | 2000 | 1433 | 0.010 |
Why?
|
Liver Diseases | 1 | 2002 | 1304 | 0.010 |
Why?
|
Health Policy | 1 | 2003 | 2699 | 0.010 |
Why?
|
Disease Management | 1 | 2001 | 2530 | 0.010 |
Why?
|
Heart Failure | 1 | 2013 | 11837 | 0.010 |
Why?
|
Heart Diseases | 1 | 2002 | 2818 | 0.000 |
Why?
|
Health Status | 1 | 2001 | 4085 | 0.000 |
Why?
|
Referral and Consultation | 1 | 2000 | 3615 | 0.000 |
Why?
|
Survival Rate | 1 | 2001 | 12822 | 0.000 |
Why?
|